With a market cap of $10.6 billion, Revvity, Inc. (RVTY) is a provider of health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Based in Waltham, Massachusetts, the company operates through Life Sciences and Diagnostics segments.

Shares of RVTY have significantly lagged behind the broader market over the past 52 weeks. RVTY has crumbled 20.7% over this time frame, while the broader S&P 500 Index ($SPX) has gained 9.8%. Moreover, shares of RVTY are down 19.5% on a YTD basis, compared to SPX’s marginal drop.

Zooming in further, Revvity has also underperformed the Health Care Select Sector SPDR Fund’s (XLV) 10% dip over the past 52 weeks and a 4.4% decline on a YTD basis. 

Revvity stock rose marginally following the release of its solid Q1 2025 results on Apr. 28. The company reported revenue of $664.8 million, a 2.3% increase from the year-ago quarter, driven by growth across both segments and surpassing the consensus estimate of $662.2 million. Adjusted EPS from continuing operations rose 3.1% year-over-year to $1.01, beating Wall Street expectations by 5.2%.

Looking ahead to fiscal 2025, RVTY expects revenue in the range of $2.8 billion to $2.9 billion, with adjusted EPS projected between $4.90 and $5.

For the current fiscal year, ending in December 2025, analysts expect RVTY’s adjusted EPS to decline 1.8% year-over-year to $4.81. However, the company's earnings surprise history is strong. It beat the consensus estimates in the past four quarters. 

Among the 17 analysts covering the stock, the consensus rating is a “Moderate Buy.” That’s based on 10 “Strong Buy” ratings, one “Moderate Buy,” and six “Holds.” 

This configuration is slightly more bullish than three months ago, with nine “Strong Buy” ratings on the stock.

On May 1, UBS lowered RVTY’s price target to $115 and upgraded it to a “Buy” rating. 

As of writing, Revvity is trading below the mean price target of $120. The Street-high price target of $135 implies a potential upside of a staggering 50.3% from the current price levels.